UroGen Pharma Other Current Liabilities

UroGen Pharma (URGN) currently reports a other current liabilities of $20M as of June 2026. That compares with $32M in the prior-year period — down 38.7% year over year. Use the charts on this page to explore UroGen Pharma's other current liabilities history and peer comparisons.

UroGen Pharma's other current liabilities decreased from $32M to $20M — a 38.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

UroGen Pharma reported $20M in other current liabilities as of June 2026. That compares with $32M in the prior-year period — down 38.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for UroGen Pharma, and consider following URGN for alerts when major investors trade the stock.

UroGen Pharma is classified in the Healthcare sector. On other current liabilities, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing URGN with unrelated industries.